Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Pancreatic Neoplasms
  • Thromboembolism

abstract

  • TEs are common in exocrine pancreatic cancer, with coagulopathy, erythropoietin-stimulating agent use, and underweight BMI influencing thrombosis timing. TEs, particularly early ones, confer a significantly worse prognosis, suggesting a biological significance, underscoring the relevance of ongoing prophylaxis trials, and raising the question of whether early TEs should be considered a stratification factor for clinical trials.

publication date

  • June 15, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.26600

PubMed ID

  • 21989534

Additional Document Info

start page

  • 3053

end page

  • 61

volume

  • 118

number

  • 12